葡萄兰 (Portulaca oleracea L.) 多糖类通过调节肠道平衡来缓解硫酸引起的性结肠炎
Ke Ning1, Chao Shi1, Yan-Yu Chi1
1Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, School of Life Sciences, Jilin University, Changchun 130012, PR China.
International journal of biological macromolecules
|November 24, 2023
概括
葡萄兰 (Portulaca oleracea L.) 聚糖 (POP) 通过减少炎症和改善肠道屏障功能来缓解性结肠炎 (UC). 这项研究揭示了POP POP.
科学领域:
- 胃肠道学和营养学
- 免疫学和微生物学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症疾病,治疗选择有限.
- 葡萄兰 (Portulaca oleracea L.) 含有具有治疗潜力的生物活性化合物.
- 在UC中,Portulaca oleracea L. 聚糖 (POP) 的特定机制尚不清楚.
研究的目的:
- 研究POP对UC的治疗作用和潜在机制.
- 在UC的小鼠模型中评估POP对肠道微生物群和结肠转录组的影响.
主要方法:
- 使用膜分离 (>10 kDa 分数) 来制备POP从草的水性提取物中.
- 在小鼠中使用硫酸 (DSS) 诱导UC.
- 在UC小鼠中评估POP对炎症,氧化应激,肠道屏障功能,肠道微生物群和结肠转录组的影响.
主要成果:
- 在DSS诱导的UC小鼠中,POP治疗显著降低了炎症和氧化应激.
- POP改善了肠道屏障的完整性,并恢复了肠道平衡.
- 通过POP调节肠道微生物组成,维持了视网醇和短链脂肪酸水平,促进了B细胞的增殖,并增加了结肠中的免疫球蛋白A表达.
结论:
- 性结肠炎的POP显示出显著的治疗潜力.
- 通过调节肠道微生物群,增强肠道屏障功能和调节免疫反应来发挥其有益作用.
- 这些发现支持POP作为管理UC的功能性食品的发展.
关键词:
B 细胞 B 细胞 B 细胞我们的肠道微生物群.在 IgA A 里面.肠道恒常性 肠道恒常性多糖是一种多糖化合物.葡萄兰 (Portulaca oleracea) L. 葡萄兰 (Portulaca oleracea) L. 葡萄兰 (Portulaca oleracea) L. 葡萄兰 (Portulaca oleracea) 葡萄兰 (Portulaca oleracea) 葡萄兰 (Portulaca oleracea) 葡萄兰 (Portulaca oleracea) 葡萄兰 (Portulaca oleracea) 葡萄兰 (Portulaca oleracea) 葡萄兰 (Portulaca oleracea) 葡萄兰 (Portulaca oleracea) 葡萄兰 (Portulaca oleracea) 葡萄兰 (L.相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
145
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145
Drugs for Treatment of Diarrhea-Predominant IBS
183
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
183
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
512
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
512
Drugs for Treatment of Constipation-Predominant IBS
180
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
180
Drugs Affecting GI Tract Motility: Other Laxatives
236
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
236
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
211
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
211


